BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Syneron Inc. Reports Third Quarter 2012 Results


11/8/2012 9:51:29 AM

YOKNEAM, Israel, Nov. 7, 2012 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, today announced third quarter 2012 financial results for the three month and nine month periods ended September 30, 2012.

(Logo: http://photos.prnewswire.com/prnh/20120528/535447 )

Third Quarter 2012 Year-Over-Year Financial Highlights Include:

  • International revenue of $40.8 million, up 8%
  • North America revenue of $19.3 million, up 1%
  • EBU1 segment revenue of $6.9 million, up 37%
  • Non-GAAP gross margin of 55.3%, up from 53.8%
  • PAD2 segment non-GAAP operating margin of 9.1%
  • Non-GAAP EPS of $0.03
  • Cash and investments portfolio of $128.4 million at September 30, 2012

2012 YTD Year-Over-Year Financial Highlights Include:

  • International revenue of $128.2 million up 16%
  • North America revenue of $62.7 million, up 11%
  • EBU segment revenue of $19.9 million, up 42%
  • Non-GAAP gross margin of 54.7%, up from 53.8%, or 52.6% up from 50.7% on a GAAP basis
  • PADsegment non-GAAP operating margin of 9.6%, or 3.7%

    Read at BioSpace.com

       

    ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES